Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;29(2):516-519.
doi: 10.3350/cmh.2023.0051. Epub 2023 Feb 20.

Systemic therapy in advanced hepatocellular carcinoma

Joseph C Ahn  1 , Nguyen H Tran  2 , Ju Dong Yang  3   4   5
Affiliations

Systemic therapy in advanced hepatocellular carcinoma

Joseph C Ahn et al. Clin Mol Hepatol. 2023 Apr.

Erratum in

No abstract available

Keywords: Hepatocellular carcinoma; Immunotherapy; Liver cancer.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Dr. Yang provides a consulting service for Exact Sciences and Gilead. Dr. Yang’s research is funded by National Institute of Health 1K08CA259534-01A1. Dr. Tran’s research is funded by National Institute of Health 1K23MD017217-01A1.

References

    1. Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. 2020;371:m3544. - PubMed
    1. Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2022 Nov 11. doi: 10.1038/s41575-022-00704-9. - PubMed
    1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. - PubMed
    1. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173. - PubMed
    1. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. RESORCE Investigators Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66. Erratum in: Lancet 2017;389:36. - PubMed